Stephen V Liu: The recent FDA approval of the MARIPOSA-2 regimen for EGFR NSCLC

Stephen V Liu shared a post on X:

”In this episode of the IASLC podcast Lung Cancer Considered, I talk about the recent FDA approval of the MARIPOSA-2 regimen of amivantamab plus chemotherapy after osimertinib for EGFR NSCLC with Drs. Karen Reckamp and William Nassib William.”

Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.